Skip to content
OpenCapital
Get started

Organon OGN Cozaar/Hyzaar — Revenue

Other product segments

Nexplanon/Implanon NXT
$201M-19.0%
Other
$87M+11.5%
Zetia
$87M+2.4%
Atozet
$85M+10.4%
Other Non-Opiod Pain, Bone and Dermatology
$68M0.0%
Hadlima
$67M+42.6%
Nasonex
$65M-9.7%
Follistim AQ
$61M-11.6%
Arcoxia
$59M-4.8%
Renflexis
$57M0.0%
Emgality
$54M+68.8%
Other Women's Health
$46M+7.0%
Singulair
$40M-45.9%
Diprospan
$35M+16.7%
Dulera
$35M-18.6%
Clarinex
$31M-8.8%
Propecia
$30M+15.4%
Fosamax
$29M-12.1%
Other Cardiovascular
$28M-6.7%
Ganirelix Acetate Injection
$26M-3.7%
Marvelon/Mercilon
$26M-33.3%
Proscar
$26M+8.3%
Vtama
$25M+4.2%
NuvaRing
$24M+9.1%
Other Biosimilars
$24M—
Vytorin
$21M-8.7%
Brenzys
$20M+42.9%
Other Respiratory
$12M-7.7%
Rosuzet
$6M+50.0%
Jada
$5M-66.7%
Ontruzant
$5M-72.2%

Similar metrics at other companies

Bristol-Myers Squibb logo
BMYCamzyos — Total Revenues
$314M+97.5%
Jazz Pharmaceuticals logo
JAZZZiihera — Revenue from Contract with Customer, Excluding Assessed Tax
$13.3M+565%
Eli Lilly logo
LLYVerzenio — Revenue
$1.3B+12.3%
Eli Lilly logo
LLYJardiance — Revenue
$1.11B+9.9%
Eli Lilly logo
LLYOther cardiometabolic health — Revenue
$905M-4.2%
Viatris logo
VTRSNorvasc — Net Sales
$210M+21.9%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's cozaar/hyzaar — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's cozaar/hyzaar — revenue?
Organon (OGN) reported cozaar/hyzaar — revenue of $57M in Q1 2026.
How has Organon's cozaar/hyzaar — revenue changed year-over-year?
Organon's cozaar/hyzaar — revenue increased by 3.6% year-over-year, from $55M to $57M.
What is the long-term trend for Organon's cozaar/hyzaar — revenue?
Over 4 years (2021 to 2025), Organon's cozaar/hyzaar — revenue has grown at a -11.4% compound annual growth rate (CAGR), from $355M to $219M.
What does cozaar/hyzaar — revenue mean?
This metric represents the total net sales generated from the Cozaar and Hyzaar product line, which are established pharmaceutical therapies used for the treatment of hypertension. Tracking these revenues provides insight into the lifecycle performance and market demand for mature cardiovascular medications within the company's established brands portfolio. It serves as a key indicator of the revenue contribution and sustainability of legacy assets as they face generic competition or market saturation.